CN108727292A - 一种奥扎莫德及其中间体的制备方法 - Google Patents
一种奥扎莫德及其中间体的制备方法 Download PDFInfo
- Publication number
- CN108727292A CN108727292A CN201710267532.5A CN201710267532A CN108727292A CN 108727292 A CN108727292 A CN 108727292A CN 201710267532 A CN201710267532 A CN 201710267532A CN 108727292 A CN108727292 A CN 108727292A
- Authority
- CN
- China
- Prior art keywords
- compound
- zhamode
- iii
- protecting group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 125000003368 amide group Chemical group 0.000 claims abstract description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 19
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003223 protective agent Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims abstract 5
- 238000007363 ring formation reaction Methods 0.000 claims abstract 2
- 125000006239 protecting group Chemical group 0.000 claims description 17
- 239000003054 catalyst Substances 0.000 claims description 10
- 239000003863 metallic catalyst Substances 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 238000006722 reduction reaction Methods 0.000 claims description 7
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003377 acid catalyst Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000006482 condensation reaction Methods 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 2
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- -1 diacetone-L- 2-KLGs Chemical compound 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 235000006040 Prunus persica var persica Nutrition 0.000 claims 1
- 240000006413 Prunus persica var. persica Species 0.000 claims 1
- 229960001270 d- tartaric acid Drugs 0.000 claims 1
- 238000006197 hydroboration reaction Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 5
- 231100000614 poison Toxicity 0.000 abstract description 2
- 230000007096 poisonous effect Effects 0.000 abstract description 2
- 238000007796 conventional method Methods 0.000 abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229950008141 ozanimod Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical class OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- VKJVXYWGRYQADR-UHFFFAOYSA-N s-tert-butylthiohydroxylamine Chemical class CC(C)(C)SN VKJVXYWGRYQADR-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/32—Separation; Purification; Stabilisation; Use of additives
- C07C253/34—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
本发明提供了奥扎莫德及其中间体的制备方法。本发明方法是以2,3‑二氢‑4‑氰基‑1‑茚酮为原料,通过合适的方法制备化合物III。采用保护剂对化合物III的胺基和羟基进行保护,制得化合物IV。将化合物IV进行盐处理得化合物V。将化合物V与化合物VI进行环合反应制得化合物VII。对化合物VII进行脱保护制得奥扎莫德。本发明方法与传统方法相比,减少了反应步骤,提高了总收率,制备产品质量高;反应条件温和,避免了危险操作条件、剧毒试剂和昂贵化学试剂的应用,不但解决了传统方法中存在的安全性问题,而且降低了成本,适合工业化生产。
Description
技术领域
本发明属于药物合成技术领域,具体涉及奥扎莫德及其中间体的制备方法。
背景技术
奥扎莫德(化学名称:5-[3-[(1S)-2,3-二氢-1-[(2-羟乙基)胺基]-1H-茚-4-基]-1,2,4-僫二唑-5-基]-2-(1-甲基乙氧基)-苯甲腈),英文名:Ozanimod。主要用于多发性硬化症、溃疡性结肠炎和克罗恩病的治疗。其中,多发性硬化症和溃疡性结肠炎不但病程长、发病率高,而且需要长年用药。可见,奥扎莫德市场容量巨大,前景可观。
美国瑞塞普托斯公司的专利CN201080061144.8公开了以(R)-(+)-2-甲基-2-丙基亚磺酰胺与4-氰基-1-茚酮为原料,通过缩合反应得到亚胺,然后再利用磺酰胺的手性进行诱导控制,钠硼氢还原后得到保护的手性胺基,在强酸性条件下水解亚磺酰基,得到手性胺基的方法。反应路线如下:
该方法存在以下缺点:
(1)反应路线长,有9步反应,存在产品生产周期长、总收率低及生产成本高的缺点,其摩尔总收率仅为31%;
(2)第一步反应中需要用到剧毒试剂氰化锌,对人体危害大,劳动保护要求高,操作不方便;
(3)第二步的反应条件要求无水无氧,对操作要求高,操作不方便;
(4)第六步用到NaH和DMF,反应安全性差,易发生爆炸;该方法制得的产品质量低,手性纯度(ee%)仅为95%;
(5)另外反应中用到价格昂贵的试剂(R)-(+)-2-甲基-2-丙基亚磺酰胺,大大提高了生产成本。
发明内容
本发明的目的在于解决以上问题,提供一种生产成本低、安全性好、适合工业化生产的奥扎莫德及其中间体的制备方法。
实现本发明上述目的的技术方案是:奥扎莫德及其中间体的制备方法,它是以 2,3-二氢-4-氰基-1-茚酮为原料,通过合适的方法制得化合物III。其后采用保护剂对化合物III的胺基和羟基进行保护,获得中间体化合物IV;其后将化合物IV与羟胺或羟胺相关的盐反应,制得中间体化合物V;其后,在合适的溶剂和碱存在下,将化合物V与化合物VI进行环合反应获得中间体化合物VII;最后,运用适当的脱保护方法脱去化合物VII的保护基,得到奥扎莫德。具体反应步骤如下:
a)以2,3-二氢-4-氰基-1-茚酮(如II所示化合物)为原料,在适当的条件下,合成化合物III。
b)化合物IV是采用保护剂对化合物III的胺基和羟基进行保护而制得的。
其中,R1为羟基保护基,R2为胺基保护基。
c)化合物V是用羟胺或羟胺相关的盐处理化合物IV制得的。
其中,R1为羟基保护基,R2为胺基保护基。
d)化合物VII是由化合物V与化合物VI发生缩合反应而得到的。
其中,R1为羟基保护基,R2为胺基保护基。
e)化合物I奥扎莫德为运用脱保护方法脱去式VII化合物的保护基而制得的。
其中,R1为羟基保护基,R2为胺基保护基。
上述的步骤a)-1:以化合物II为原料,在催化剂存在下,经不对称还原反应制备化合物III。
上述的步骤a)-2:以化合物II为原料,与氨基乙醇缩合,在适当溶剂下,用还原剂进行还原得到化合物III的消旋体式III-A,化合物III-A在手性酸条件下进行拆分,获得化合物III。
上述的步骤a)-1,以化合物II为原料,在催化剂存在下,经不对称还原反应制备化合物III,所述的催化剂选自金属催化剂、手性磷酸催化剂或手性磺酸催化剂中至少一种,其中金属催化剂选自含有Ru,Ni,Cu,Pt或Co金属的金属催化剂;上述的的步骤a)-2,以化合物II为原料,,用还原剂进行还原反应得到化合物III 的消旋体式III-A,化合物III-A在手性酸条件下进行拆分,获得化合物III。上述还原反应的的还原剂为硼氢化物、四氢锂铝、氢气、甲酸或甲酸盐中至少一种;上述的手性拆分反应方法的手性拆分剂为D-扁桃酸、D-酒石酸、D-樟脑酸、D- 樟脑磺酸、D-乳酸、D-苹果酸、双丙酮-L-古龙酸、D-谷氨酸中的至少一种;
如式IV所示化合物;
其中,R1为H或羟基保护基;R2为H或胺基保护基。
如式V所示化合物。
其中,R1为H或羟基保护基;R2为H或胺基保护基。
如式VII所示化合物。
其中,R1为H或羟基保护基;R2为H或胺基保护基。
本发明的积极效果在于:
(1)本发明缩短了Ozanimod的合成步骤,只有5-6步反应,不仅缩短了产品的生产周期,而且提高了产品的摩尔总收率和质量。
(2)本发明方法避免了安全性差的NaH、DMF组合试剂及价格昂贵的试剂 (R)-(+)-2-甲基-2-丙基亚磺酰胺的应用,而是采用价格便宜的绿色化原辅料,不仅提高了反映的安全性,而且降低了反应的成本。
(3)本发明反应条件温和,避免了无水无氧的操作步骤,操作简便,易于实现。
(4)本发明的路线设计新颖,所得5个反应中间体均为全新化合物,生产过程环境友好,安全可靠,总收率高,成本低,适合工业化生产。
具体实施方式
以下实施例是说明性的,不意在限制要求保护的发明范围。
实施例1
在氮气保护下,向包含化合物II(15.7克,0.1摩尔)的三颈瓶中加入二氯甲烷(400毫升),依次加入含Ru的金属催化剂(0.80克,0.001摩尔)、碘(0.127克,0.001 摩尔)、(S,S)-f-1,2-双[4,5-二羟基-3H-联苯磷]苯(0.80克,0.001摩尔),在20℃下常压下氢化24小时,溶液经硅藻土过滤后,依次用饱和亚硫酸钠水溶液、饱和氯化钠水溶液洗涤有机层,经无水硫酸钠干燥后,过滤浓缩,得到白色固体18.0克,纯度99%,收率90%。
1HNMR(400MHz,DMSO)δ 7.50-7.31(m,3H),4.04(m,1H),3.62(q,2H,J=5.5Hz),3.57-3.43(m,1H),3.27(ddd,1H ,J1=17.6Hz,J2=9.1Hz,J3=5.0Hz),3.15-2.85(m,1H),2.74(m,2H),2.58(dtd,1H,J1=9.0 Hz,J2=5.5Hz,J3=5.3Hz,J4=3.6Hz),2.20(ddd,1H,J1=13.4Hz,J2=8.9Hz,J3=4.6Hz).
实施例1A-实施例1B
实施例1A-实施例1B的制备方法与实施例1基本相同,不同之处在于催化剂不同,具体见表1。
表1
催化剂 | 摩尔收率 | |
实施例1 | 含Ru金属催化剂 | 90% |
实施例1A | 含Co金属催化剂 | 86% |
实施例1B | 手性磷酸催化剂 | 84% |
实施例1C | 手性磺酸催化剂 | 73% |
实施例2
(1)还原反应
在氮气保护下,向包含式II的化合物(15.7克,0.1摩尔)的三颈瓶中加入四氢呋喃(400毫升),并将反应物冷却至-78℃,在30分钟内分批加入硼氢化钠(3.4克, 0.1摩尔)。在-78℃下反应30分钟,然后在1小时内升温至0℃。用饱和氯化钠水溶液 (100毫升)淬灭反应,加入饱和酒石酸钠钾水溶液(420毫升)淬灭反应,用乙酸乙酯(1500毫升)稀释反应混合物,分液,有机层依次用饱和氯化铵、水和饱和氯化钠洗涤。有机层用硫酸镁干燥,过滤,浓缩滤液,得到棕色油状物13.6克,不用纯化直接用于下一步反应。
(2)手性拆分
在氮气保护下,将式III-A的化合物(20.2克,0.1摩尔)溶解在异丙醇(100毫升)中,在室温下慢慢滴加D-乙酰扁桃酸的异丙醇溶液(19.4克溶解在50毫升异丙醇中, 0.1摩尔),搅拌1小时后,过滤,滤饼用丁酮/正庚烷重结晶,得到白色固体,即化合物III的扁桃酸盐。将所得的白色固体溶解在纯化水(100毫升)中,用饱和碳酸钾水溶液中和至pH至9-10,析出白色固体,过滤,滤饼用水淋洗,减压下干燥,得到式 III的化合物7.2克,纯度99%,收率35%。
1HNMR(400MHz,DMSO)δ 7.50-7.31(m,3H),4.04(m,1H),3.62(q,2H,J=5.5Hz),3.57-3.43(m,1H),3.27(ddd,1H ,J1=17.6Hz,J2=9.1Hz,J3=5.0Hz),3.15-2.85(m,1H),2.74(m,2H),2.58(dtd,1H,J1=9.0 Hz,J2=5.5Hz,J3=5.3Hz,J4=3.6Hz),2.20(ddd,1H,J1=13.4Hz,J2=8.9Hz,J3=4.6Hz).
实施例2A-实施例2C
实施例2A-实施例2C制备方法步骤(1)与实施例2的步骤(1)基本相同,不同之处在于还原剂不同,具体见表2。实施例2A-实施例2C制备方法步骤(2)与实施例2的步骤(2)相同。
表2
还原剂 | 摩尔收率 | |
实施例2 | 硼氢化钠 | 35% |
实施例2A | 四氢锂铝 | 38% |
实施例2B | 乙酸 | 41% |
实施例2C | 氢气 | 26% |
实施例2D-实施例2H
实施例2D-实施例2H制备方法的步骤(1)与实施例2的步骤(1)相同,实施例2D- 实施例2H制备方法的步骤(2)与实施例2的步骤(2)基本相同,不同之处在于拆分剂不同,具体见表3。
表3
实施例3
在氮气保护下,将式III的化合物(20.2克,0.1摩尔)溶解在丙酮(100毫升)中,在室温下加入对甲苯磺酸吡啶盐(2.85克,0.01摩尔)和2,2-二甲氧基丙烷(10.2克, 0.12摩尔),搅拌3小时后,通过硅胶垫过滤,滤去色素,得到无色溶液,减压下浓缩得白色固体,干燥,得到式IV-1的化合物23.4克,纯度99%,收率96.7%。
1HNMR(400MHz,DMSO)δ 7.50-7.31(m,3H),4.08(m,1H,J=6.1Hz),3.62(q,2H,J=5.5Hz),3.57-3.43(m,1H),3.2 7(ddd,1H,J1=17.6Hz,J2=9.1Hz,J3=5.0Hz),3.15-2.85(m,1H,J=24.2Hz),2.58(dtd,1H ,J1=9.0Hz,J2=5.5Hz,J3=5.3Hz,J4=3.6Hz),2.48(ddd,1H,J1=13.4Hz,J2=8.9Hz,J3=4.6H z),1.30(s,6H).
实施例3A实施例3B
实施例3A制备方法与实施例3基本相同,不同之处在于保护剂不同,具体见表4。
表4
保护剂 | 摩尔收率 | |
实施例3 | 2,2-二甲氧基丙烷 | 96.7% |
实施例3A | 三乙基氯硅烷 | 95.3% |
实施例4
在氮气保护下,向式IV-1的化合物(24.2克,0.1摩尔)的乙醇(200毫升)溶液中加入盐酸羟胺(21.0克,0.3摩尔)和三乙胺(30.3克,0.3摩尔)。在80℃下回流反应混合物4小时。将反应混合物冷却至室温,并浓缩至干,然后用二氯甲烷(500毫升) 稀释。用碳酸氢钠、水和盐水洗涤有机层。合并有机层经硫酸镁干燥,并浓缩以产生28.3克白色泡沫状固体,即式V-1的化合物,不经纯化可直接用于下一步反应。
实施例5
在氮气保护下,向式V-1的化合物(27.5克,0.1摩尔)的N,N-二甲基甲酰胺(110 毫升)溶液中加入羧酸VI(20.5克,0.1摩尔),碳化二亚胺(23.0克,0.12摩尔)和 1-羟基苯并三唑(16.2克,0.12摩尔)。在室温下反应2小时,然后将反应混合物加热至80℃,反应12小时。将反应混合物冷却至室温,并用乙酸乙酯(250毫升)稀释。用NaHCO3、水和盐水洗涤有机层。合并有机层经MgSO4干燥,并浓缩以产生46.0 克白色泡沫状固体,即式VI-1的化合物,不经纯化可直接用于下一步反应。
1HNMR(400MHz,DMSO)δ8.53(d,1H,J=2.3Hz), 8.42(dd,1H,J1=7.6Hz,J2=2.3Hz),8.17(d,1H,J=7.7Hz),7.97(d,1H,J=7.6Hz),7.63-7 .50(m,2H),5.28(t,1H,J=5.0Hz),4.99(m,1H,J=6.1Hz),4.92(s,1H),3.62(q,2H,J=5. 5Hz),3.57-3.43(m,1H),3.27(ddd,1H, J1=17.6Hz,J2=9.1Hz,J3=5.0Hz),3.15-2.85(m,2H,J=24.2Hz),2.58(dtd,1H,J1=9.0Hz, J2=5.5Hz,J3=5.3Hz,J4=3.6Hz),2.48(ddd,1H,J1=13.4Hz,J2=8.9Hz,J3=4.6Hz),1.39(d ,6H,J=6.0Hz),1.30(s,6H).
实施例6
在氮气保护下,向式VII-1的化合物(44.4克,0.1摩尔)的甲醇溶液(110毫升) 溶液中加入浓盐酸(5毫升,0.06摩尔),在室温下反应2小时,析出白色固体,过滤,减压下烘干即式I的化合物,白色固体26.8克,纯度99%,收率66.3%。
1HNMR(400MHz,DMSO)δ9.25(s,2H),8.53(d,1H,J=2.3Hz), 8.42(dd,1H,J1=7.6Hz,J2=2.3Hz),8.17(d,1H,J=7.7Hz),7.97(d,1H,J=7.6Hz),7.63-7 .50(m,2H),5.28(t,1H,J=5.0Hz),4.99(m,1H,J=6.1Hz),4.92(s,1H),3.72(q,2H,J=5. 5Hz),3.57-3.43(m,1H),3.27(ddd,1H, J1=17.6Hz,J2=9.1Hz,J3=5.0Hz),3.15-2.85(m,2H,J=24.2Hz),2.53(dtd,1H,J1=9.0Hz, J2=5.5Hz,J3=5.3Hz,J4=3.6Hz),2.30(ddd,1H,J1=13.4Hz,J2=8.9Hz,J3=4.6Hz),1.39(d ,6H,J=6.0Hz).。
Claims (9)
1.奥扎莫德及其中间体的制备方法,该方法包括以下步骤:以2,3-二氢-4-氰基-1-茚酮为原料,经合适的方法制得化合物III。采用保护剂对化合物III的胺基和羟基进行保护,制得化合物IV。将化合物IV进行盐处理得化合物V。将化合物V与化合物VI进行环合反应制得化合物VII。对化合物VII进行脱保护制得奥扎莫德。
a)以2,3-二氢-4-氰基-1-茚酮(如II所示化合物)为原料,在适当的条件下,合成化合物III。
b)化合物IV是采用保护剂对化合物III的胺基和羟基进行保护而制得的。
其中,R1为羟基保护基,R2为胺基保护基。
c)化合物V是用羟胺或羟胺相关的盐处理化合物IV制得的。
其中,R1为羟基保护基,R2为胺基保护基。
d)化合物VII是由化合物V与化合物VI发生缩合反应而得到的。
其中,R1为羟基保护基,R2为胺基保护基。
e)化合物I奥扎莫德为运用脱保护方法脱去式VII化合物的保护基而制得的。
其中,R1为羟基保护基,R2为胺基保护基。
2.根据权利要求1所述的奥扎莫德的制备方法,其特征在于,所述的步骤a)为以化合物II为原料,在催化剂存在下,经不对称还原反应制备化合物III。
3.根据权利要求1所述的奥扎莫德的制备方法,其特征在于,所述的步骤a)为以化合物II为原料,与氨基乙醇缩合,在适当溶剂下,用还原剂进行还原得到化合物III的消旋体式III-A,化合物III-A在手性酸条件下进行拆分,获得化合物III。
4.根据权利要求2所述的奥扎莫德中间体化合物III的制备方法,其特征在于,所述的催化剂选自金属催化剂、手性磷酸催化剂或手性磺酸催化剂中至少一种。其中金属催化剂选自含有Ru,Ni,Cu,Pt或Co金属的金属催化剂。
5.根据权利要求3所述的奥扎莫德的制备方法,其特征在于,所述的还原剂为硼氢化物、四氢锂铝、氢气、甲酸或甲酸盐中至少一种。
6.根据权利要求1所述的奥扎莫德的制备方法,其特征在于,所述的手性拆分剂为D-扁桃酸、D-酒石酸、D-樟脑酸、D-樟脑磺酸、D-乳酸、D-苹果酸、双丙酮-L-古龙酸、D-谷氨酸中的至少一种。
7.如式IV所示化合物。
其中,R1为H或羟基保护基;R2为H或胺基保护基。
8.如式V所示化合物。
其中,R1为H或羟基保护基;R2为H或胺基保护基。
9.如式VII所示化合物。
其中,R1为H或羟基保护基;R2为H或胺基保护基。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710267532.5A CN108727292A (zh) | 2017-04-21 | 2017-04-21 | 一种奥扎莫德及其中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710267532.5A CN108727292A (zh) | 2017-04-21 | 2017-04-21 | 一种奥扎莫德及其中间体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108727292A true CN108727292A (zh) | 2018-11-02 |
Family
ID=63933651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710267532.5A Pending CN108727292A (zh) | 2017-04-21 | 2017-04-21 | 一种奥扎莫德及其中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108727292A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
WO2020115200A1 (en) * | 2018-12-07 | 2020-06-11 | Synthon B.V. | Improved process for preparing ozanimod |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102724880A (zh) * | 2009-11-13 | 2012-10-10 | 瑞塞普托斯公司 | 1-磷酸鞘氨醇受体调节剂及手性合成方法 |
CN102762100A (zh) * | 2009-11-13 | 2012-10-31 | 瑞塞普托斯公司 | 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法 |
WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
WO2016164180A1 (en) * | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
-
2017
- 2017-04-21 CN CN201710267532.5A patent/CN108727292A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102724880A (zh) * | 2009-11-13 | 2012-10-10 | 瑞塞普托斯公司 | 1-磷酸鞘氨醇受体调节剂及手性合成方法 |
CN102762100A (zh) * | 2009-11-13 | 2012-10-31 | 瑞塞普托斯公司 | 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法 |
WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
WO2016164180A1 (en) * | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
Non-Patent Citations (1)
Title |
---|
WEN-JING WU ET AL.: "Molecular Snuggle and Stretch of a Tetraammonium Chain in the Construction of a Hetero-[4]pseudorotaxane with CyclopentanoQ[6] and Classical Q[7]", 《J. ORG. CHEM.》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
WO2020115200A1 (en) * | 2018-12-07 | 2020-06-11 | Synthon B.V. | Improved process for preparing ozanimod |
US11390593B2 (en) | 2018-12-07 | 2022-07-19 | Synthon B.V. | Process for preparing ozanimod |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109956870A (zh) | 一种罗沙司他的合成方法及其中间体化合物 | |
CN110615744A (zh) | 一种布瓦西坦中间体及其制备方法 | |
Tang et al. | Synthesis of a water-soluble cationic chiral diamine ligand bearing a diguanidinium and application in asymmetric transfer hydrogenation | |
CN108727292A (zh) | 一种奥扎莫德及其中间体的制备方法 | |
CN108727291A (zh) | 奥扎莫德及其中间体的制备方法 | |
CN107098822A (zh) | 一种制备普仑司特关键中间体3‑氨基‑2‑羟基苯乙酮的制备方法 | |
CN113248432B (zh) | 高收率制备罗沙司他中间体的新方法 | |
CN105085323B (zh) | 达芦那韦中间体的合成新工艺 | |
CN106518939B (zh) | 一种制备Solithromycin化合物的方法 | |
CN114716405A (zh) | 一种芳香性苯并[c]菲啶类生物碱中间体化合物的制备方法及用途 | |
CN109280055A (zh) | 麦角类生物碱的不对称合成方法 | |
CN107216332A (zh) | 叔丁基‑7‑羟甲基‑7,8‑二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法 | |
CN106946724A (zh) | 单胺基抑制剂类中间体2‑乙酰氨基‑2‑苄基丙二酸单乙酯的合成方法 | |
CN103992238B (zh) | 3-氨基水杨酸的制备方法 | |
CN109678738B (zh) | 一种合成(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 | |
CN102382051A (zh) | 异喹啉酮及其衍生物的制备方法 | |
WO2019214749A1 (zh) | 非金属路易斯酸催化烯烃分子内加成c-o键合成苯并呋喃衍生物的方法 | |
CN105111134A (zh) | 一种制备(r)-或(s)-3-氨基哌啶双盐酸盐的方法 | |
CN112479993A (zh) | 一种应用于kras抑制剂类药物杂环中间体的合成方法 | |
CN111925333A (zh) | 一种2-氨基-5-甲基吡嗪的制备方法及产品与应用 | |
CN105001096B (zh) | 一种制备4‑氨基‑n‑烷基苄胺的方法 | |
JPS62255456A (ja) | ジエチルホルムアミドの製造方法 | |
SE442512B (sv) | Forfarande for framstellning av 3',4'-dideoxikanamycin b | |
JP7454498B2 (ja) | サリチルアミド酢酸塩の製造方法 | |
CN115925511B (zh) | 一种中间体4,4-二氟环己醇的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181102 |
|
WD01 | Invention patent application deemed withdrawn after publication |